Navigation Links
Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
Date:10/30/2007

ed improvements of 2.1, 3.4 and 2.1 minutes, respectively, compared to placebo. For the dose group of 100 mg, this observation of improvement was statistically significant (p < 0.05).

Further evidence of the wake-promoting properties of VSF-173 was also observed during the scheduled daytime recovery sleep following the night time and morning evaluations. Statistically significant (p<.05; non-parametric) dose-dependent correlations were observed with the following polysomnography (PSG) parameters: increased number of awakenings, decreased sleep efficiency and total sleep time for the first third of the sleep period, and increased wake time after sleep onset for the first 3 hours of the sleep period.

These wake-promoting effects of VSF-173 on MWT and PSG measures suggest that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. Vanda plans to conduct additional studies to further understand timing of administration, dose-response and appropriate populations to treat. VSF-173 was also demonstrated to be safe and well-tolerated.

"We are encouraged by the results of this proof-of-concept study on VSF-173," stated Mihael Polymeropoulos, M.D., President and CEO of Vanda. "We believe that the compound has the potential to address the symptoms of excessive sleepiness in the context of a number of disorders including narcolepsy and shift worker sleep disorder, as well as neurodegenerative disorders."

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company with a particular focus on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. In addition to VSF-173, Vanda is developing Iloperidone, a drug for schizophrenia, which has recently been submitted for marketing approval to the FDA, and VEC-162, a compound for the treatment of sleep and mood disorders, which h
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Top 10 Best SEO Hosting, a ... GoDaddy and Bluehost are among the best web ... most recommended suppliers for webmasters from the USA, ... quality Linux hosting (including VPS and cloud hosting). ... many top hosting companies that started thinking Green. ...
(Date:9/19/2014)... Ticket Down has slashed ticket prices ... Tour. This popular ticket reseller is offering their customer ... , Ariana Grande 2015 Honeymoon Tour Dates: , Feb. 25, ... 2015: Milwaukee, WI (BMO Harris Bradley Center) , March 01, ... 2015: Chicago, IL (Allstate Arena) , March 05, 2015: Cleveland, ...
(Date:9/19/2014)... TORONTO, Sept. 19, 2014 York University researchers ... movement can help to detect heightened risk for ... there are any telltale behavioural signs of dementia., ... candidate Kara Hawkins who led the study asked ... and cognitive-motor tasks, on dual screen laptop computers. ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... over the five years to 2014. Industry operators were ... time during the period, as well as establish distribution ... is due in large part to its novelty; energy ... Nevertheless, in that time, industry operators have been able ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... by technological advancements, surgical techniques, and immunosuppressant drugs ... preferred treatment for several chronic diseases related to ... in organ and tissue transplantation have phenomenally revolutionized ... Organ transplant today represents a pivotal medical ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4
... president and founder of Allergy & Asthma Network Mothers ... patient access to all forms of 12-hour bronchodilators at ... Drug Safety and Risk Management Advisory Committee and Pediatric ... in Rockville, MD. , , ...
... provider of hair removal information and consultation scheduling on the ... for guests to locate and learn about consumer-rated laser clinics ... In recent weeks, Hair Removal Forum,s "Doctor Finder" function has ... in a number of unique ways. On the main doc ...
... 11 Based on its recent,analysis of ... recognizes,SourceOne Global Partners with the 2008 United ... methodically readying Cholesstrinol(TM) (a platform for,its multiple ... for,the marketplace. From establishing conclusive scientific evidence ...
... sophisticated gas analyzer that,measures carbon dioxide (CO2) under pressure ... CO2 dilutes explosive ... sterilizers and research laboratories. (EtO is both,toxic and extremely ... of intermolecular energy transfer between EtO and CO2 (and,nitrogen, ...
... professionals to use their clinical judgment to choose what is best ... , ST. PETERSBURG, Fla., Dec. 11 ... NYSE: SNN ) is pleased to announce the introduction ... The new dressing kits will be launched in the market ...
... & Gamble,Company (NYSE: PG ) is holding ... at 8:30 a.m. Eastern Time. Chairman of the ... executive management team will,provide a review of the company,s ... Mr. Lafley will ...
Cached Medicine News:Health News:AANMA Provides Commentary to FDA Advisory Committees Reviewing Benefit-Risk Assessment of 12 Hour Bronchodilators 2Health News:Hair Removal Forum Unveils New 'Doctor Finder' Interface 2Health News:Frost & Sullivan Awards SourceOne Global Partners for Proprietary Heart Health Formulas 2Health News:Frost & Sullivan Awards SourceOne Global Partners for Proprietary Heart Health Formulas 3Health News:Frost & Sullivan Awards SourceOne Global Partners for Proprietary Heart Health Formulas 4Health News:Frost & Sullivan Awards SourceOne Global Partners for Proprietary Heart Health Formulas 5Health News:New Analyzer Measures CO2 at High Pressures 2Health News:Introducing the Smith & Nephew Foam Dressing Kit 2Health News:Introducing the Smith & Nephew Foam Dressing Kit 3Health News:Introducing the Smith & Nephew Foam Dressing Kit 4Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 2Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 3Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 4
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... today announced that The New England Journal ... II data for the investigational drug iniparib* (BSI-201) ... triple negative breast cancer (mTNBC) when iniparib was ...
... 2011 MiMedx Group, Inc.  (OTC Bulletin ... and marketer of patent protected biomaterial-based products, announced today ... leader in the development of tissue processing techniques for ... amnion membranes. The deal was originally announced on December ...
Cached Medicine Technology:Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 2Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 3Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 4Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 5Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 6MiMedx Completes Acquisition of Surgical Biologics 2MiMedx Completes Acquisition of Surgical Biologics 3MiMedx Completes Acquisition of Surgical Biologics 4
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: